Publication

Article

CURE

Summer 2009
Volume8
Issue 2

Childhood Cancer Survivorship Programs

Childhood cancer survivors need long-term surveillance to keep up with late-term effects, screenings, and other health-related issues.

Childhood cancer survivors need lifelong follow-up care to monitor for secondary cancers, long-term and late effects, and other health-related issues. Below are a list of programs that provide survivorship care to childhood cancer survivors.

http://beyondthecure.org/resources/follow-up-clinics.html.

The National Children’s Cancer Society provides a listing of long-term follow-up clinics for survivors of childhood cancer at

Other Childhood Cancer Survivors Programs:

Children’s Hospital Los Angeles LIFE Program (Long-term Information, Follow-Up and Evaluation)

www.childrenshospitalla.org/site/c.ipINKTOAJsG/b.4347877/k.899B/LIFE_Program.htm

City of Hope Childhood Cancer Survivorship Program

www.cityofhope.org/survivorship

HEROS Clinic at Yale Cancer Center

www.med.yale.edu/pediat/hem_onc/heros/index.html

UCLA’s Jonsson Comprehensive Cancer Center Pediatric Long-Term Follow-Up Program

www.cancer.ucla.edu/Index.aspx?page=222

UCSF Survivors of Childhood Cancer Program

www.ucsfhealth.org/childrens/special/s/100903.html

University of Chicago Comer Children’s Hospital Childhood Cancer Survivors Center

www.uchicagokidshospital.org/specialties/cancer/survivors/index.html

UT Southwestern Medical Center and Children’s Medical Center in Dallas' After the Cancer Experience

www.childrens.com/ace

Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Related Content